Prescient Therapeutics’ PTX-100 Shows Promise in CTCL

Prescient Therapeutics Limited (AU:PTX) has released an update.

Prescient Therapeutics Limited has announced that their latest clinical data for PTX-100, a drug targeting T-cell lymphomas, will be presented at the prestigious World Congress of Cutaneous Lymphomas. An additional patient achieved a partial response in their Phase 1b trial, reinforcing PTX-100’s potential as a therapy for the orphan disease cutaneous T-cell lymphoma. The company is gearing up for a Phase 2 study later this year, buoyed by the overall positive response rates and safety profile observed in the trials.

For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.